GlassScriptPhysician profile
Susan Buford
NPI 1841969060
$10,756.32
in general payments reported to CMS, 2019-2025
38 companies · $2,786 in 2025
The $2,786 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $131 · 2022: $2,321 · 2023: $2,556 · 2024: $2,962 · 2025: $2,786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,304.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,789.48 | 2022-2025 | |
| Janssen Biotech, INC. | $1,459.35 | 2022-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $909.51 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $877.85 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $765.29 | 2022-2025 | |
| Genzyme Corporation | $569.12 | 2022-2025 | |
| Ardelyx, INC. | $410.02 | 2022-2025 | Ibsrela |
| Lilly USA, LLC | $309.15 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $240.75 | 2023-2025 | Dupixent |
| Pfizer INC. | $240.33 | 2021-2025 | |
| Braintree Laboratories, INC. | $238.44 | 2021-2024 | Sutab, Suflave |
| Ironwood Pharmaceuticals, INC | $202.52 | 2022-2024 | Linzess |
| Janssen Scientific Affairs, LLC | $201.61 | 2022-2023 | Stelara |
| Aimmune Therapeutics, INC. | $180.00 | 2024-2025 | Zenpep |
| Qol Medical, LLC | $133.50 | 2023-2025 | Sucraid, Sucraid |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $128.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Amgen INC. | $105.86 | 2022-2025 | Amjevita, Avsola |
| Nestle Healthcare Nutrition INC. | $98.56 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $80.93 | 2022-2024 | Zerbaxa, Recarbrio, Dificid |
| Organon LLC | $72.89 | 2022-2025 | Hadlima, Renflexis |
| Ipsen Biopharmaceuticals, INC | $68.91 | 2024 | Iqirvo, Bylvay |
| Phathom Pharmaceuticals, INC. | $65.97 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $65.66 | 2022-2025 | |
| Celgene Corporation | $64.37 | 2023-2024 | Zeposia |
| Alnylam Pharmaceuticals INC. | $60.37 | 2022-2024 | Givlaari |
| Vivus LLC | $58.25 | 2025 | Pancreaze |
| Redhill Biopharma INC. | $52.11 | 2022-2023 | Talicia, Aemcolo, Movantik |
| Fresenius Kabi USA, LLC | $49.70 | 2024 | Idacio |
| Ferring Pharmaceuticals INC. | $40.63 | 2023 | Rebyota |
| Daiichi Sankyo INC. | $33.56 | 2022 | |
| Sandoz INC. | $31.92 | 2023-2024 | Hyrimoz |
| Surmodics, INC. | $27.46 | 2023-2024 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Thrombectomy, Pounce Venous Thrombectomy System |
| Sirtex Medical INC | $26.60 | 2025 | Sir-Spheres Microspheres |
| Novo Nordisk INC | $25.13 | 2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $19.20 | 2023 | Leqvio |
| Pharmacosmos Therapeutics INC. | $18.74 | 2023 | Monoferric |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.41 | 2024 | Cyltezo |
| Echosens North America, INC. | $15.71 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Buford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.